Dianthus Therapeutics DNTH Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's change in deferred revenue?
- Dianthus Therapeutics (DNTH) reported change in deferred revenue of $849K in Q1 2026.
- How has Dianthus Therapeutics's change in deferred revenue changed year-over-year?
- Dianthus Therapeutics's change in deferred revenue increased by 1589.5% year-over-year, from -$57K to $849K.
- What is the long-term trend for Dianthus Therapeutics's change in deferred revenue?
- Over 2 years (2022 to 2024), Dianthus Therapeutics's change in deferred revenue has grown at a 63.7% compound annual growth rate (CAGR), from $891K to $2.39M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.